Project: Novel therapy for intractable tumours bearing oncogenic Kras mutations

This project will employ a novel approach in order to develop a therapeutic agent to combat tumours bearing mutations in a specific gene, in particular Kras mutations, this representing a biomarker that predicts poor disease prognosis. The project will deliver a Novel Chemical Entity (NCE) with proven therapeutic properties against cancer and with a known safety profile.

Acronym	TARGETIN’RAS (Reference Number: 10407)
Duration	01/09/2016 - 01/03/2019
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 5

Project partner

Number	Name	Role	Country
23968	Allinky Biopharma SL	Coordinator	Spain
23969	Sequani Limited	Partner	United Kingdom
23970	Crelux GmbH	Partner	Germany